Pipeline

ATA3219

ATA3219: Developing Off-the-Shelf Allogeneic CD19 Program for B-Cell Malignancies, With IND Expected in Q2 2023

Academic program generated proof of principle for EBV T-cell platform potential to generate off-the-shelf, allogeneic CAR T immunotherapies ATA3219: Next-generation off-the-shelf, allogeneic CD19-1XX CAR+ EBV T-cell immunotherapy containing a modified CD3ζ signaling domain, 1XX.

Curran KJ, Sauter CS, Kernan NA, et al. Durable remission following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-cells in patients with relapse/refractory (R/R) B-cell malignancies. Biol Blood Marrow Transplant. 2020;26(3):S89. IND = Investigational New Drug

ATA3219

Allogeneic CAR T targeting CD19, currently in preclinical development, leverages our EBV T-cell platform and features a next-generation 1XX co-stimulatory domain.

LEARN MORE arrow_forward_ios

Indication
Pre-clinical
Phase 1
Phase 2
Phase 3

ATA3219: B-cell malignancies
Pre-clinical
- Target: CD19
- Technologies: Novel CAR T 1XX co-stimulation
- Off-the-shelf, allogeneic

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.